共 50 条
- [21] Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Javle, Milind M.Borbath, IvanClarke, Stephen JohnHitre, ErikaLouvet, ChristopheMercade, Teresa MacarullaOh, Do-YounSpratlin, Jennifer L.Valle, Juan W.Weiss, Karl HeinzBerman, CraigHowland, MichaelYe, YiningCho, TerryMoran, SusanAbou-Alfa, Ghassan K.
- [22] Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO TrialCLINICAL CANCER RESEARCH, 2016, 22 (12) : 2960 - 2968Jovelet, CecileIleana, EcaterinaLe Deley, Marie-CecileMotte, NellyRosellini, SilviaRomero, AlfredoLefebvre, CelinePedrero, MarionPata-Merci, NoemieDroin, NathalieDeloger, MarcMassard, ChristopheHollebecque, AntoineFerte, CharlesBoichard, AmeliePostel-Vinay, SophieNgo-Camus, MaudDe Baere, ThierryVielh, PhilippeScoazec, Jean-YvesVassal, GillesEggermont, AlexanderAndre, FabriceSoria, Jean-CharlesLacroix, Ludovic
- [23] Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2)ANNALS OF ONCOLOGY, 2020, 31 : S261 - S262Bridgewater, J.Meric-Bernstam, F.Hollebecque, A.Valle, J. W.Morizane, C.Karasic, T.Abrams, T.Furuse, J.Kelley, R. K.Cassier, P.Klumpen, H-J.Uboha, N.Mahipal, A.Mitchell, E.Ahn, E. R.Chang, H-M.Masuda, K.He, Y.Benhadji, K.Goyal, L.
- [24] Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterationsANNALS OF ONCOLOGY, 2023, 34 : S231 - S232Garmezy, B.Borad, M.Lin, C. C.Chen, L. T.Perez, C. A.Kato, S.Tam, B.Severson, P.Quah, C. S.Harding, J. J.
- [25] Circulating Cell-Free DNA-Based Comprehensive Molecular Analysis of Biliary Tract Cancers Using Next-Generation SequencingCANCERS, 2022, 14 (01)Csoma, Szilvia LillaBedekovics, JuditVeres, Gergoarokszallasi, AnitaAndras, CsillaMehes, GaborMokanszki, Attila
- [26] Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trialANNALS OF ONCOLOGY, 2019, 30 : 62 - 62Javle, M.Borbath, I.Clarke, S.Hitre, E.Louver, C.Macarulla, T.Oh, D.Spratlin, J.Valee, J.Weiss, K.Berman, C.Howland, M.Ye, Y.Cho, T.Moran, S.Abou-Alfa, C.
- [27] Early detection of cancer using cell-free DNA (cfDNA) size analysis on a multiplexed amplicon-based next-generation sequencing (NGS) platformJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Choudhury, YuktiPinweha, PannapaPoh, JonathanLim, Jing ShanTan, Min-Han
- [28] Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation studyCELL DEATH & DISEASE, 2019, 10 (7)Alborelli, IlariaGenerali, DanieleJermann, PhilipCappelletti, Maria RosaFerrero, GiuseppinaScaggiante, BrunaBortul, MarinaZanconati, FabrizioNicolet, StefanHaegele, JasminBubendorf, LukasAceto, NicolaScaltriti, MaurizioMucci, GiuseppeQuagliata, LucaNovelli, Giuseppe
- [29] Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation studyCell Death & Disease, 10Ilaria AlborelliDaniele GeneraliPhilip JermannMaria Rosa CappellettiGiuseppina FerreroBruna ScaggianteMarina BortulFabrizio ZanconatiStefan NicoletJasmin HaegeleLukas BubendorfNicola AcetoMaurizio ScaltritiGiuseppe MucciLuca QuagliataGiuseppe Novelli
- [30] Next-Generation Sequencing Panel Analysis of Clinically Relevant Mutations in Circulating Cell-Free DNA from Patients with Gestational Trophoblastic Neoplasia: A Pilot StudyBIOMED RESEARCH INTERNATIONAL, 2020, 2020Luo, LingxiaoLin, LingZhang, XiaoyanCai, QingqingZhao, HongboXu, CongjianCong, Qing